Topic

All

20
Jul
2020

Barring Foreign Talent Is An Assault on Biotech Innovation

As a first generation American (John Maraganore) and a proud immigrant (Jeremy Levin), we’re appalled by the relentless, short-sighted assaults by this Administration on legal immigration. The latest attempt specifically aims to limit, and potentially shut down, immigration to America of the world’s best and brightest minds. This is precisely the time we need these bright minds. Thankfully, in light...
Read More
20
Jul
2020

Clinical Trials: High-Value Attack Surface For Pharmatech Entrepreneurs

There’s an emerging sense among early stage investors that there are profound opportunities at the intersection of healthcare and technology, and no shortage of white papers from consultants and venture groups addressing this topic. Consultant white papers tend to be focused on the inevitability of “digital transformation,” emphasize the $X billion dollar opportunity, and argue that if large organizations don’t...
Read More
15
Jul
2020

Do We Need Models Anymore?

Long ago, in the early days of the pandemic, models were everywhere in the news. As our lives were upended and everything became uncertain, models were there to provide some predictability in the face of the unknown. Never mind that predictions varied wildly – between models, and even within the same model at different time points. The models agreed that...
Read More
13
Jul
2020

Playing the Long Game for Antibiotic R&D

This week’s unveiling of the AMR Action Fund, a $1 billion public/private consortium anchored by 23 pharmaceutical companies to support the development and commercialization of antibiotics, is a welcome development in the fight against antimicrobial resistant infections.   The money is important, but it was very encouraging to see the leadership of major pharmaceutical companies — Pfizer, Merck, and Eli...
Read More
11
Jul
2020

Can Novartis Digitally Transform Clinical Development?

In 2018, Dr. Vas Narasimhan, newly-installed as CEO, told the Wall Street Journal he saw Novartis as “a focused medicines company that’s powered by data science and digital technologies.”  Since then, Novartis has tried to grow into this ambition, embracing the concept of digital transformation perhaps more conspicuously than any other large pharma.  It’s not easy, as Narasimhan himself acknowledged...
Read More
10
Jul
2020

The Remdesivir Pricing Letter Gilead Should Have Written

Dear America, We’ve decided to grossly underprice remdesivir. Hundreds of thousands of COVID-19 patients in America, and even more around the world, need our drug. But the US insurance system is corrupt and heartless. It has demonstrated that it will go to great lengths to prevent patients from getting appropriate, physician-prescribed treatments. You know their tricks: high deductibles, high copays,...
Read More
6
Jul
2020

Writing in the Language of DNA: Kevin Ness on The Long Run

Today’s guest on The Long Run is Kevin Ness. He’s the CEO of Boulder, CO-based Inscripta. This is a startup that calls itself the “digital genome engineering company.” The aspiration, which Inscripta described in a statement last December, was to create: The world’s first fully automated benchtop instrument for genome-scale engineering. Consisting of an instrument, consumables, software, and assays, it...
Read More
29
Jun
2020

Q&A with Regeneron SVP David Weinreich on Therapeutic Neutralizing Antibodies

Public discussion about the role of biotech and pharma in the pandemic tends to focus on one of two areas. Vaccines are the great hope, and occupy center stage. Gilead’s remdesivir has captured considerable attention, largely by being the first approved drug for COVID-19, despite offering a limited benefit for hospitalized patients. Off in the periphery of the public mind...
Read More